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Introduction
Pulmonary hypertension (PH) is characterised by
increased pulmonary arterial blood pressure, vascular
remodelling of the small pulmonary arteries, right ven-
tricular hypertrophy and ultimately right ventricular fail-
ure. Whether idiopathic (primary PH) or secondary (due
to chronic lung disease, congenital heart disease or HIV
infection), the disease carries a high mortality and mor-
bidity, primarily because of the lack of selective pulmo-
nary vasodilators. Current treatment options include
prostacyclin analogues (e.g. epoprostenol) and the
endothelin receptor antagonist bosentan; however, these
agents suffer from many drawbacks including the need for
parenteral administration and, like other vasodilators
(e.g. calcium channel blockers), have significant systemic
hypotensive effects. Recently, the phosphodiesterase 5
(PDE V) inhibitor sildenafil has been licensed for the
treatment of PH. Sildenafil is orally active, has selective
pulmonary vasodilator effects and improves exercise tol-
erance in patients with PH [1], thus representing a signif-
icant advance over existing therapy. In addition, attention
has focused on novel combination therapies for PH (e.g.
sildenafil plus iloprost) [2] or by increasing cGMP levels
by activating soluble guanylate cyclase (sGC; e.g. inhaled
NO, BAY 41–2272) [3].
The mechanism(s) underlying the pulmonary selectivity
of sildenafil remain unclear. Although sildenafil reduces
functional and structural changes in many animal models
of PH, the pulmonary selectivity of sildenafil is blunted in
animals lacking the natriuretic peptide receptor (NPR)-A
[4]. This suggests that the mechanism of pulmonary selec-
tivity of PDE V inhibition is dependent, at least in part, on
the bioactivity of natriuretic peptides and activation of the
particulate isoform of guanylate cyclase. Thus, we have
explored the interaction(s) of PDE V inhibitors and the
natriuretic peptide system in vitro and in vivo, including an
animal model of PH, to more fully elucidate the
(patho)physiological relationship between these two
cGMP-regulating systems.
Results
Using classical organ bath pharmacology to assess the
reactivity of isolated aortic and pulmonary artery smooth
muscle from the rat, we observed that sildenafil augments
relaxations to the NO-donor, spermine NONOate, in
both vessel types. In marked contrast, sildenafil only
enhances the vasodilator activity of atrial natriuretic pep-
tide (ANP) in the pulmonary artery. Furthermore, the in
vivo hypotensive effect of ANP is augmented by sildenafil
specifically in the pulmonary resistance vasculature. These
data suggest a specific role for PDE V in the modulation of
pulmonary (but not systemic) responses to natriuretic
peptides in the mouse in vitro and in vivo. This gives rise to
the possibility of effecting organ- or vessel-specific altera-
tions in the vasodilator activity of natriuretic peptides,
which may represent an important physiological regula-
tory mechanism and may be of therapeutic benefit in PH.
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To address the latter possibility, we explored the benefi-
cial effects of sildenafil, the neutral endopeptidase inhibi-
tor ecadotril (prevents natriuretic peptide breakdown and
thereby augments plasma levels of these peptides), and a
combination of sildenafil plus ecadotril, on vascular func-
tion and pulmonary remodelling in an animal model of
hypoxia-induced PH. Our results indicate that a combina-
tion of sildenafil plus ecadotril is superior to either drug
alone in reversing many indices of disease progression
and severity including increased pulmonary artery pres-
sure, right ventricular hypertrophy and pulmonary vascu-
lar remodelling. Importantly, a combination of sildenafil
plus ecadotril had no significant effect on systemic blood
pressure.
Conclusion
These data imply that manipulating the natriuretic pep-
tide system can enhance the pulmonary selectivity of PDE
5 inhibitors and may offer a better means of treating PH
than PDE V inhibitors alone or in combination with acti-
vation of the soluble isoform of GC (particularly in terms
of avoiding systemic hypotension). Moreover, these find-
ings give clear evidence for compartmentalisation of
cGMP-dependent signalling between the soluble and par-
ticulate guanylate cyclases and differential regulation of
cGMP metabolism by PDEs between vascular beds.
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